Low-dose rituximab in autoimmune hemolytic anemia: 10 years after.

Bruno Fattizzo,Anna Zaninoni,Loredana Pettine,Francesca Cavallaro,Eros Di Bona,Wilma Barcellini

Blood（2019）

引用 22|浏览26

暂无评分

摘要

TO THE EDITOR:Rituximab is becoming the preferred second-line choice for steroid-refractory warm autoimmune hemolytic anemia (wAIHA) and the first-line choice for cold agglutinin disease (CAD). However, rituximab is an expensive treatment that is not available worldwide; it is also not in

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要